Diabetic Kidney Disease Diagnosis and Management

Initial Evaluation

The presence of significant hematuria in a diabetic patient is not typical of diabetic kidney disease and requires prompt evaluation, according to the American Diabetes Association, with a strength of evidence level of high 1, 2
Glucosuria reflects hyperglycemia and poor glycemic control, which is expected in uncontrolled diabetes, with a strength of evidence level of moderate 3
Trace protein in urinalysis is minimal and does not meet criteria for significant albuminuria, which would require a UACR ≥30 mg/g for diagnosis, with a strength of evidence level of high 1, 3
Negative nitrites and leukocytes effectively rule out urinary tract infection as the cause of symptoms, with a strength of evidence level of high 3

The American Diabetes Association and KDIGO guidelines recommend nephrology referral for uncertainty about the etiology of kidney disease, atypical features suggesting non-diabetic kidney disease, eGFR <30 mL/min/1.73 m², and continuously increasing urinary albumin levels or decreasing eGFR, with a strength of evidence level of high 1, 4, 5
Immediate nephrology referral is indicated based on the presence of significant hematuria in a diabetic patient, which suggests non-diabetic kidney disease, with a strength of evidence level of high 1, 4, 5

Serum creatinine and eGFR should be obtained to assess kidney function and stage any CKD, with a strength of evidence level of high 1, 3, 4
Urine albumin-to-creatinine ratio (UACR) should be measured to quantify albuminuria, with a strength of evidence level of high 1, 3, 5
Complete metabolic panel, including electrolytes, bicarbonate, calcium, and phosphate, should be obtained, with a strength of evidence level of moderate 4, 5
Hemoglobin A1c should be measured to assess glycemic control, with a strength of evidence level of high 2, 3
Urinalysis microscopy should be performed to quantify red blood cells and look for casts, which may indicate glomerulonephritis, with a strength of evidence level of high 1, 4

The American Diabetes Association recommends optimizing diabetes management by targeting HbA1c per individualized goals, with a strength of evidence level of high 2, 3
SGLT2 inhibitor should be initiated or optimized if eGFR ≥20 mL/min/1.73 m², with a strength of evidence level of high 1, 2, 3
Blood pressure should be controlled with ACE inhibitor or ARB if albuminuria is confirmed, with a strength of evidence level of high 1, 2, 3